ECSP10010321A - Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol - Google Patents

Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol

Info

Publication number
ECSP10010321A
ECSP10010321A EC2010010321A ECSP10010321A ECSP10010321A EC SP10010321 A ECSP10010321 A EC SP10010321A EC 2010010321 A EC2010010321 A EC 2010010321A EC SP10010321 A ECSP10010321 A EC SP10010321A EC SP10010321 A ECSP10010321 A EC SP10010321A
Authority
EC
Ecuador
Prior art keywords
diseases
treatment
compounds
imidazol
atoms
Prior art date
Application number
EC2010010321A
Other languages
English (en)
Inventor
Sven Weiler
Leo Widler
Jean-Michel Rondeau
Simona Cotesta
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010321A publication Critical patent/ECSP10010321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen ácidos [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfónicos sustituidos por alquilo de 2 a 5 átomos de carbono, así como métodos o procesos para su fabricación, su uso en la fabricación de formulaciones farmacéuticas, su uso en el tratamiento de enfermedades, métodos para utilizarlos en el tratamiento de enfermedades, formulaciones farmacéuticas que los abarcan, y/o los compuestos para utilizarse en el tratamiento de enfermedades. Los compuestos son capaces de inhibir la resorción ósea excesiva o inapropiada, y para el tratamiento de otras enfermedades que sean causadas por una prenilación excesiva de las proteínas objetivo, tales como síndrome de progeria de Hutchinson-Gilford. Los compuestos son de la Fórmula I, en donde uno de R1 y R2 es hidrógeno, y el otro es alquilo de 2 a 5 átomos de carbono que está ramificado o no ramificado, y que pueden estar en forma libre, o en la forma de un éster, y/o de una sal.
EC2010010321A 2007-11-30 2010-06-30 Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol ECSP10010321A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122016 2007-11-30

Publications (1)

Publication Number Publication Date
ECSP10010321A true ECSP10010321A (es) 2010-08-31

Family

ID=39154111

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010321A ECSP10010321A (es) 2007-11-30 2010-06-30 Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol

Country Status (24)

Country Link
US (2) US7977323B2 (es)
EP (1) EP2225252B1 (es)
JP (1) JP5244917B2 (es)
KR (1) KR20100092035A (es)
CN (1) CN101835787A (es)
AR (1) AR069437A1 (es)
AU (1) AU2008328797B2 (es)
BR (1) BRPI0819902A2 (es)
CA (1) CA2701516A1 (es)
CL (1) CL2008003545A1 (es)
CO (1) CO6280421A2 (es)
CR (1) CR11362A (es)
EA (1) EA201000860A1 (es)
EC (1) ECSP10010321A (es)
ES (1) ES2386851T3 (es)
IL (1) IL204657A0 (es)
MA (1) MA31895B1 (es)
MX (1) MX2010005786A (es)
NZ (1) NZ584219A (es)
PE (1) PE20091038A1 (es)
TN (1) TN2010000138A1 (es)
TW (1) TW200932248A (es)
WO (1) WO2009068567A1 (es)
ZA (1) ZA201001992B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110034418A1 (en) * 2008-04-04 2011-02-10 Karen Beltz Pharmaceutical composition with bisphosphonate
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2459176B1 (en) 2009-07-31 2017-09-27 Grünenthal GmbH Crystallization method and bioavailability
CA2836175A1 (en) 2010-05-28 2011-12-01 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
WO2019076269A1 (zh) 2017-10-16 2019-04-25 清华大学 甲羟戊酸通路抑制剂及其药物组合物
CN112980809B (zh) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3776880D1 (de) 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
ES2069424T3 (es) * 1991-02-26 1995-05-01 Procter & Gamble Pharma Metodos para el tratamiento de la osteoporosis.
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
PE20081043A1 (es) 2006-10-05 2008-09-17 Novartis Ag Composicion farmaceutica que comprende bifosfonatos
EP2139888A2 (en) 2007-03-28 2010-01-06 Array Biopharma, Inc. Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors

Also Published As

Publication number Publication date
NZ584219A (en) 2012-03-30
TN2010000138A1 (en) 2011-09-26
EP2225252A1 (en) 2010-09-08
AU2008328797B2 (en) 2011-11-03
TW200932248A (en) 2009-08-01
CR11362A (es) 2010-06-14
CL2008003545A1 (es) 2009-06-05
BRPI0819902A2 (pt) 2015-05-19
US20090143337A1 (en) 2009-06-04
MA31895B1 (fr) 2010-12-01
KR20100092035A (ko) 2010-08-19
MX2010005786A (es) 2010-06-09
IL204657A0 (en) 2010-11-30
US7977323B2 (en) 2011-07-12
JP5244917B2 (ja) 2013-07-24
AR069437A1 (es) 2010-01-20
EA201000860A1 (ru) 2010-12-30
EP2225252B1 (en) 2012-06-27
ZA201001992B (en) 2010-12-29
CN101835787A (zh) 2010-09-15
AU2008328797A1 (en) 2009-06-04
US20110224173A1 (en) 2011-09-15
JP2011504908A (ja) 2011-02-17
CA2701516A1 (en) 2009-06-04
ES2386851T3 (es) 2012-09-03
WO2009068567A1 (en) 2009-06-04
CO6280421A2 (es) 2011-05-20
PE20091038A1 (es) 2009-08-19

Similar Documents

Publication Publication Date Title
ECSP10010321A (es) Bisfosfonatos de alquilo de 2 a 5 átomos de carbono-imidazol
CR10250A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
MX377255B (es) Lipidos y composiciones de lipidos para el suministro de agentes activos.
BR112012030923B8 (pt) Composto derivado de piperidinona como inibidor de mdm2 e composição farmacêutica compreendendo o mesmo
BRPI0512690A (pt) análogos de fosfonato de compostos inibidores de hiv
CR20160127A (es) Pesticidas de azoles bicíclicos sustituidos con heterociclos
CO6450621A2 (es) Sulfonamidas nematocidas
AR061974A1 (es) Derivados de pirimidina como inhibidores de alk, composiciones farmaceuticas y procesos de obtencion
UY29122A1 (es) Serinamidas sustituidas por benzoilo
BRPI0809770B8 (pt) Composto e composição para controlar uma praga de invertebrados
UA110924C2 (uk) Мезоіонні пестициди
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UY28878A1 (es) Compuestos de aril-o heteroarilamida ortosustituidos y composiciones
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
AR105080A1 (es) Compuestos inhibidores de la señalización de la vía de notch
BR112015010941A2 (pt) pró-fármacos de gemcitabina e suas utilizações
PE20090880A1 (es) Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
CO6660462A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
PH12012501805A1 (en) Crystalline salts of a potent hcv inhibitor
EA201390939A1 (ru) Новое замещенное производное изохинолина
AR056502A1 (es) Empleo de ésteres de lactato para mejorar el efecto de los agentes protectores de las plantas